BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang LQ, Li SJ, Cao YF, Man XB, Yu WF, Wang HY, Wu MC. Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 2003; 9(2): 359-363 [PMID: 12532467 DOI: 10.3748/wjg.v9.i2.359] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Soyka M, Backmund M, Schmidt P, Apelt S. Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study. Am J Addict 2014;23:563-9. [PMID: 25251050 DOI: 10.1111/j.1521-0391.2014.12131.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
2 Delcò F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Dose adjustment in patients with liver disease. Drug Saf 2005;28:529-45. [PMID: 15924505 DOI: 10.2165/00002018-200528060-00005] [Cited by in Crossref: 144] [Cited by in F6Publishing: 103] [Article Influence: 9.0] [Reference Citation Analysis]
3 Shah RR. Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules. Expert Opinion on Drug Safety 2005;4:103-28. [DOI: 10.1517/14740338.4.1.103] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
4 Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging 2010;27:417-33. [PMID: 20450239 DOI: 10.2165/11536540-000000000-00000] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
5 Yang L, Song J, Irwin MG, Song J, Sun Y, Yu W. A clinical prospective comparison of anesthetics sensitivity and hemodynamic effect among patients with or without obstructive jaundice: Obstructive jaundice and sensitivity to isoflurane/remifentanil anesthesia. Acta Anaesthesiologica Scandinavica 2010;54:871-7. [DOI: 10.1111/j.1399-6576.2010.02222.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
6 Andreassen TN, Klepstad P, Davies A, Bjordal K, Lundström S, Kaasa S, Dale O. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol 2011;67:493-506. [PMID: 21140139 DOI: 10.1007/s00228-010-0948-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
7 Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ. Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis. JAIDS Journal of Acquired Immune Deficiency Syndromes 2008;49:358-68. [DOI: 10.1097/qai.0b013e31818c7efe] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
8 Snider NT, Walker VJ, Hollenberg PF. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications. Pharmacol Rev 2010;62:136-54. [PMID: 20133390 DOI: 10.1124/pr.109.001081] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 6.8] [Reference Citation Analysis]
9 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Boston: Springer US; 2005. pp. 377-530. [DOI: 10.1007/0-387-27447-2_10] [Cited by in Crossref: 176] [Cited by in F6Publishing: 95] [Reference Citation Analysis]
10 Congiu M, Mashford ML, Slavin JL, Desmond PV. Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease. J Gastroenterol Hepatol. 2009;24:1038-1044. [PMID: 19638083 DOI: 10.1111/j.1440-1746.2009.05800.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
11 Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009;37:2087-94. [PMID: 19651758 DOI: 10.1124/dmd.109.027466] [Cited by in Crossref: 188] [Cited by in F6Publishing: 184] [Article Influence: 14.5] [Reference Citation Analysis]
12 Ramsden D, Fung C, Hariparsad N, Kenny JR, Mohutsky M, Parrott NJ, Robertson S, Tweedie DJ. Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates. Drug Metab Dispos 2019;47:1206-21. [PMID: 31439574 DOI: 10.1124/dmd.119.087270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Anderson GD, Hakimian S. Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment. Clin Pharmacokinet 2014;53:29-49. [PMID: 24122696 DOI: 10.1007/s40262-013-0107-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
14 Lenoir C, Rollason V, Desmeules JA, Samer CF. Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature. Front Pharmacol 2021;12:733935. [PMID: 34867341 DOI: 10.3389/fphar.2021.733935] [Reference Citation Analysis]
15 Morcos PN, Cleary Y, Sturm-Pellanda C, Guerini E, Abt M, Donzelli M, Vazvaei F, Balas B, Parrott N, Yu L. Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib. J Clin Pharmacol 2018;58:1618-28. [PMID: 30052269 DOI: 10.1002/jcph.1286] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
16 Ye L, Yang X, Guo E, Chen W, Lu L, Wang Y, Peng X, Yan T, Zhou F, Liu Z. Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient. PLoS One 2014;9:e96664. [PMID: 24797816 DOI: 10.1371/journal.pone.0096664] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
17 Cho SJ, Kim SB, Cho HJ, Chong S, Chung SJ, Kang IM, Lee JI, Yoon IS, Kim DD. Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet. J Agric Food Chem 2016;64:5598-606. [PMID: 27321734 DOI: 10.1021/acs.jafc.6b01663] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
18 Wang Y, Xing X, Cao Y, Zhao L, Sun S, Chen Y, Chai Y, Chen S, Zhu Z. Development and Application of an UHPLC-MS/MS Method for Comparative Pharmacokinetic Study of Eight Major Bioactive Components from Yin Chen Hao Tang in Normal and Acute Liver Injured Rats. Evid Based Complement Alternat Med 2018;2018:3239785. [PMID: 30519262 DOI: 10.1155/2018/3239785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005;44:661-80. [PMID: 15966752 DOI: 10.2165/00003088-200544070-00001] [Cited by in Crossref: 189] [Cited by in F6Publishing: 155] [Article Influence: 11.8] [Reference Citation Analysis]
20 Jearapong N, Chatuphonprasert W, Jarukamjorn K. Effect of tetrahydrocurcumin on the profiles of drug-metabolizing enzymes induced by a high fat and high fructose diet in mice. Chemico-Biological Interactions 2015;239:67-75. [DOI: 10.1016/j.cbi.2015.06.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
21 He R, Li Y, Ruan J. Serum alanine transaminase total bilirubin concentrations predict CYP3A activity as measured by midazolam and 1'-hydroxylation. Med Sci Monit 2015;21:396-402. [PMID: 25648948 DOI: 10.12659/MSM.892044] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
22 Sidharta PN, Treiber A, Dingemanse J. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. Clin Pharmacokinet 2015;54:457-71. [PMID: 25860376 DOI: 10.1007/s40262-015-0255-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
23 Di S, Han L, An X, Kong R, Gao Z, Yang Y, Wang X, Zhang P, Ding Q, Wu H, Wang H, Zhao L, Tong X. In silico network pharmacology and in vivo analysis of berberine-related mechanisms against type 2 diabetes mellitus and its complications. J Ethnopharmacol 2021;276:114180. [PMID: 33957209 DOI: 10.1016/j.jep.2021.114180] [Reference Citation Analysis]
24 Priou P, Gagnadoux F, Dehé C, Hureaux J, Person C, Urban T, Racineux JL. [Drug-induced pneumonitis in a patient treated with venlafaxine and propanolol]. Rev Mal Respir 2008;25:610-3. [PMID: 18535530 DOI: 10.1016/s0761-8425(08)71620-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
25 Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004;27:145-72. [PMID: 14756578 DOI: 10.2165/00002018-200427030-00001] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 4.6] [Reference Citation Analysis]
26 Dostalek M, Court MH, Yan B, Akhlaghi F. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol 2011;163:937-47. [PMID: 21323901 DOI: 10.1111/j.1476-5381.2011.01270.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 7.1] [Reference Citation Analysis]
27 Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend 2014;144:1-11. [PMID: 25179217 DOI: 10.1016/j.drugalcdep.2014.07.035] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 7.6] [Reference Citation Analysis]
28 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Cham: Springer International Publishing; 2015. pp. 523-785. [DOI: 10.1007/978-3-319-12108-6_9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
29 Ge Y, Chen S, Mu W, Ba Q, Li J, Chen P, Wang X, Wang H. Epigenetic regulation of UDP-Glucuronosyltransferase by microRNA-200a/-183: implications for responses to sorafenib treatment in patients with hepatocellular carcinoma. Cancer Lett 2019;454:14-25. [PMID: 30910587 DOI: 10.1016/j.canlet.2019.03.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
30 Vuppalanchi R, Liang T, Goswami CP, Nalamasu R, Li L, Jones D, Wei R, Liu W, Sarasani V, Janga SC. Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis. PLoS One. 2013;8:e74471. [PMID: 24058572 DOI: 10.1371/journal.pone.0074471] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
31 El-khateeb E, Vasilogianni A, Alrubia S, Al-majdoub ZM, Couto N, Howard M, Barber J, Rostami-hodjegan A, Achour B. Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice. Pharmacology & Therapeutics 2019;203:107397. [DOI: 10.1016/j.pharmthera.2019.107397] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
32 Zhang C, Xu Y, Gao P, Lu J, Li X, Liu D. Down-regulation of carboxylesterases 1 and 2 plays an important role in prodrug metabolism in immunological liver injury rats. International Immunopharmacology 2015;24:153-8. [DOI: 10.1016/j.intimp.2014.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
33 Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, Cherrington NJ. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol 2008;82:959-64. [PMID: 18488193 DOI: 10.1007/s00204-008-0312-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
34 Berger B, Dingemanse J, Sabattini G, Delahaye S, Duthaler U, Muehlan C, Krähenbühl S. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clin Pharmacokinet 2021. [PMID: 34002356 DOI: 10.1007/s40262-021-01028-8] [Reference Citation Analysis]
35 Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49:189-206. [PMID: 20170207 DOI: 10.2165/11318160-000000000-00000] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 10.3] [Reference Citation Analysis]
36 Denne C, Vogl-Voswinckel AE, Gruebl A, Burdach S. Adrenal crisis caused by inhaled fluticasone in an adolescent with cystic fibrosis and advanced hepatopathy: a case report. Case Rep Pulmonol 2012;2012:913574. [PMID: 23056987 DOI: 10.1155/2012/913574] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Chen X, Cui X, Pognan N, Quinlan M, Kapoor S, Rahmanzadeh G, Giovannini M, Marbury TC. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study. Br J Clin Pharmacol 2021. [PMID: 34046915 DOI: 10.1111/bcp.14929] [Reference Citation Analysis]
38 Xu XB, Cai JX, Dong JH, He ZP, Han BL, Leng XS. Effects of different operations on cirrhotic portal hypertensive liver in rats. Shijie Huaren Xiaohua Zazhi 2004; 12(3): 689-693 [DOI: 10.11569/wcjd.v12.i3.689] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Ahn CY, Bae SK, Bae SH, Kim T, Jung YS, Kim YC, Lee MG, Shin WG. Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis. Br J Pharmacol 2009;156:1019-28. [PMID: 19226288 DOI: 10.1111/j.1476-5381.2008.00105.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
40 Shoieb SM, El-ghiaty MA, Alqahtani MA, El-kadi AO. Cytochrome P450-derived eicosanoids and inflammation in liver diseases. Prostaglandins & Other Lipid Mediators 2020;147:106400. [DOI: 10.1016/j.prostaglandins.2019.106400] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
41 Ogaly HA, Eltablawy NA, El-Behairy AM, El-Hindi H, Abd-Elsalam RM. Hepatocyte Growth Factor Mediates the Antifibrogenic Action of Ocimum bacilicum Essential Oil against CCl4-Induced Liver Fibrosis in Rats. Molecules 2015;20:13518-35. [PMID: 26213907 DOI: 10.3390/molecules200813518] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
42 Fanni D, Pinna F, Gerosa C, Paribello P, Carpiniello B, Faa G, Manchia M. Anatomical distribution and expression of CYP in humans: Neuropharmacological implications. Drug Dev Res 2021;82:628-67. [PMID: 33533102 DOI: 10.1002/ddr.21778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
43 Bednasz CJ, Venuto CS, Ma Q, Morse GD. Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications. Clin Pharmacol Drug Dev 2017;6:135-9. [PMID: 28263465 DOI: 10.1002/cpdd.313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Shah RR. Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol 2004;58:452-69. [PMID: 15521892 DOI: 10.1111/j.1365-2125.2004.02228.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
45 Bϋdingen FV, Gonzalez D, Tucker AN, Derendorf H. Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments. Ther Adv Infect Dis 2014;2:17-42. [PMID: 24949199 DOI: 10.1177/2049936113519089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
46 El-Khateeb E, Darwich AS, Achour B, Athwal V, Rostami-Hodjegan A. Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment. Aliment Pharmacol Ther 2021;54:388-401. [PMID: 34218453 DOI: 10.1111/apt.16489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]